Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
A live audio-only Webcast of this presentation can be accessed beginningat 6:30 PM Central Time on June 2, 2008 through a link posted on the Nektarwebsite: http://www.nektar.com/wt/page/asco. A replay will also be accessiblethrough the same link through June 15, 2008.
To attend this event in person, please RSVP no later than Sunday, June 1,2008 to Vanessa Rivas: firstname.lastname@example.org.
Nektar Therapeutics is a biopharmaceutical company that develops andenables differentiated therapeutics with its industry-leading PEGylation andpulmonary drug development platforms. Nektar PEGylation technology hasenabled eight approved products for partners, which include leadingpharmaceutical and biotechnology companies. Nektar also develops its ownproducts by applying its PEGylation and pulmonary technology platforms toexisting medicines with the objective to enhance performance, such asimproving efficacy, safety and compliance.
Contact: Jennifer Ruddock, +1-650-283-6253, email@example.comTime: 6:00 - 6:30 PM (Central Time) -- Registration 6:30 PM (Central Time) -- Webcast presentation Location: Fulton's on the River Riverfront Room and Veranda 315 N. LaSalle Street Chicago, IL 60610
SOURCE Nektar Therapeutics
You May Also Like